17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial

Combs, C. Andrew; Garite, Thomas J.; Maurel, Kimberly; Das, Anita; Porto, Manuel

doi:10.1016/j.ajog.2010.12.042

Cited by 106 publications

(84 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The lack of efficacy of 17OHP-C in the prevention of preterm birth in our study is consistent with the reports that 17OHP-C does not reduce the rate of preterm birth in patients with twins, [28][29][30] triplets, 31,32 or a short cervix 22 (defined as <30 mm or the subgroup analysis reported by the investigators).…”

Section: Clinical Meaning Of the Studysupporting

confidence: 94%

“…This suggests that our population was truly at risk. Another strength was that we used a high dose of 17OHP-C (500 mg weekly vs 250 mg in other studies 15,22,[28][29][30][31][32] ). We chose 17OHP-C as the progestogen because of the finding of the study of Meis et al 15 We opted for a 500 mg/wk dose of 17OHP-C, reasoning that this higher dose may be more effective than the 250 mg dose of 17OHP-C previously used.…”

Section: Strengths and Limitations Of The Studymentioning

confidence: 99%

See 1 more Smart Citation

17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial

Winer

Bretelle

Sénat

et al. 2015

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

Section: Clinical Meaning Of the Studysupporting

confidence: 94%

Section: Strengths and Limitations Of The Studymentioning

confidence: 99%

17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial

Winer

Bretelle

Sénat

et al. 2015

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

“…28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 Eighteen studies provided data on both monochorionic and dichorionic,16 30 32 34 36 38 40 42 43 44 45 48 49 50 51 54 56 57 seven on only monochorionic,29 31 37 39 41 47 53 and seven on only dichorionic twin pregnancies 2833 35 46 52 55 58 Twenty three authors provided relevant unpublished data 1628 30 32 33 34 35 38 39 41 42 43 47 48 49 50 51 52 53 54 56 57 58…”

Section: Resultsmentioning

confidence: 99%

“…33 35 46 52 55 58 Twenty three authors provided relevant unpublished data 1628 30 32 33 34 35 38 39 41 42 43 47 48 49 50 51 52 53 54 56 57 58…”

Section: Resultsmentioning

confidence: 99%

Prospective risk of stillbirth and neonatal complications in twin pregnancies: systematic review and meta-analysis

Cheong-See

Schuit

Arroyo-Manzano

et al. 2016

BMJ

Self Cite

188

150

View full text Add to dashboard Cite

Objective To determine the risks of stillbirth and neonatal complications by gestational age in uncomplicated monochorionic and dichorionic twin pregnancies.Design Systematic review and meta-analysis.Data sources Medline, Embase, and Cochrane databases (until December 2015). Review methods Databases were searched without language restrictions for studies of women with uncomplicated twin pregnancies that reported rates of stillbirth and neonatal outcomes at various gestational ages. Pregnancies with unclear chorionicity, monoamnionicity, and twin to twin transfusion syndrome were excluded. Meta-analyses of observational studies and cohorts nested within randomised studies were undertaken. Prospective risk of stillbirth was computed for each study at a given week of gestation and compared with the risk of neonatal death among deliveries in the same week. Gestational age specific differences in risk were estimated for stillbirths and neonatal deaths in monochorionic and dichorionic twin pregnancies after 34 weeks’ gestation.Results 32 studies (29 685 dichorionic, 5486 monochorionic pregnancies) were included. In dichorionic twin pregnancies beyond 34 weeks (15 studies, 17 830 pregnancies), the prospective weekly risk of stillbirths from expectant management and the risk of neonatal death from delivery were balanced at 37 weeks’ gestation (risk difference 1.2/1000, 95% confidence interval −1.3 to 3.6; I2=0%). Delay in delivery by a week (to 38 weeks) led to an additional 8.8 perinatal deaths per 1000 pregnancies (95% confidence interval 3.6 to 14.0/1000; I2=0%) compared with the previous week. In monochorionic pregnancies beyond 34 weeks (13 studies, 2149 pregnancies), there was a trend towards an increase in stillbirths compared with neonatal deaths after 36 weeks, with an additional 2.5 per 1000 perinatal deaths, which was not significant (−12.4 to 17.4/1000; I2=0%). The rates of neonatal morbidity showed a consistent reduction with increasing gestational age in monochorionic and dichorionic pregnancies, and admission to the neonatal intensive care unit was the commonest neonatal complication. The actual risk of stillbirth near term might be higher than reported estimates because of the policy of planned delivery in twin pregnancies.Conclusions To minimise perinatal deaths, in uncomplicated dichorionic twin pregnancies delivery should be considered at 37 weeks’ gestation; in monochorionic pregnancies delivery should be considered at 36 weeks.Systematic review registration PROSPERO CRD42014007538.

show abstract

“…Subanalysen der anderen Studien zur Prävention der Frühgeburt durch die Gabe von Progesteron konnten dies bestä-tigen [40,48,49,50,51] …”

Section: Progesteron Und Mehrlingsgraviditätunclassified

Progesteron zur Prävention der Frühgeburt

Nonnenmacher

2012

Gynäkologe

View full text Add to dashboard Cite

Frühgeburten sind weltweit die Hauptursache für perinatale Morbidität und Mortalität [1]. Neueren Schät-zungen zufolge waren in 2005 weltweit von allen Geburten, 12,9 Mio. (9,8%) Frühgeburten; von ihnen etwa 11 Mio. (85%) in Afrika und Asien, 500.000 jeweils in Europa und Nordamerika und 900.000 in Lateinamerika und der Karibik. Die höchste Rate an Frühgeburten haben Afrika (11,9%) und Nordamerika (10,6%), die niedrigste Europa (6,2%) [2]. Die Zahl der Frühgeburten ist in Europa in den letzten 10 Jahren in fast allen Ländern gestiegen. Im Jahr 2007 lag die Frühgeburtenrate in Deutschland bei 7,1% [3]. In den USA ist die Rate an Frühgeburten in den letzten 25 Jahren um 36% von 9,4% 1981 auf 12,8% 2006 gestiegen. Dieser Anstieg ist zum Teil auf Probleme in der Schwangerschaft, die durch die assistierte Reproduktion entstehen, zurückzuführen [4, 5].

show abstract

17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial

Cited by 106 publications

References 19 publications

17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial

17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial

Prospective risk of stillbirth and neonatal complications in twin pregnancies: systematic review and meta-analysis

Progesteron zur Prävention der Frühgeburt

Contact Info

Product

Resources

About